GlaxoSmithKline PLCNYSE:GSK
Symbol Lookup
Refresh
Recent News»
0 New Today| Company | Market Cap | P/E Ratio (TTM) | EPS Growth (5yr) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novartis AG NVS | 201.3B | 19.0x | +6.79% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Sanofi SA SNY | 144.8B | 22.7x | -0.79% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Pfizer Inc PFE | 205.4B | 20.5x | +1.33% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Roche Holding AG RHHBY | 220.7B | 22.0x | -0.02% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Johnson & Johnson JNJ | 247.4B | 24.0x | +1.22% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Data delayed 15 minutes. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Company Information
GlaxoSmithKline plc (GSK) is global healthcare group, which is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products. GSK's principal pharmaceutical products include medicines in therapeutic areas: respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, antibacterials, oncology and emesis, dermatology, rare diseases, immuno-inflammation, vaccines and human immunodeficiency virus (HIV). The Company operates in three primary areas of business: Pharmaceuticals, Vaccines and Consumer Healthcare. On January 31, 2012, the Company completed the divestment of brands in the United States and Canada to Prestige Brands Holdings. In August 2012, it acquired Human Genome Sciences. On January 30, 2013, GSK acquired additional 29.3% interest in GlaxoSmithKline Consumer Healthcare Ltd.
| Headquarters | C8 Gsk House, 980 Great West Road BRENTFORD, ENG, United Kingdom TW8 9GS |
|---|---|
| Phone | 208-047-5000 |
| Fax | 208-047-7807 |
EXECUTIVE OFFICERS
| Chief Executive Officer, Executive Director | Andrew Witty |
|---|---|
| Chief Financial Officer, Executive Director | Simon Dingemans |
| Chairman - Research & Development, Executive Director | Moncef Slaoui |
| President - North American Pharmaceuticals | Deirdre Connelly |
| President - Global Manufacturing & Supply | Roger Connor |
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
With TD Waterhouse, you have access to the industry's leading selection of independent research reports from providers such as TDSI, TD Securities, S&P, INK and Argus.
Open a New Account, or Login if you're a client.
(GAAP)*
| Market Cap | $128.8B | Beta | 0.64 |
|---|---|---|---|
| Revenue (TTM) | $39.8B | EPS | $2.54 |
| Shares Out. | 2.5B | Book Value | $3.60 |
| Dividend Yield | 4.49% | P/E | 20.6x |
| Annual Dividend Rate | $2.35 | Price/Sales (TTM) | 3.2 |
| Ex-Div Date | 5/8/13 | P/Cash Flow (TTM) | 14.1x |
| Pay Date | 8/8/13 | Operating Margin | 26.49% |
*GAAP = prior to non-GAAP analyst adjusted earnings.
(Non-GAAP)*
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
